Patent for Sale:Extracorporeal Medical Device for the Treatment of Severe Sepsis
The technology will potentially be able to efficiently eradicate even the most drug resistant organisms by using the laws of physics rather than chemical (drug) reactions. The Company’s in vitro studies demonstrate that UV irradiation is 90 to 99 percent efficient in eliminating bacteria, while potentially allowing the body’s natural blood constituents to survive in a healthy state. Perhaps more importantly, the system is intended to make antibiotics currently used even more effective and improve patient outcomes. Used pro-actively, the Company believes that the system will lead to more economic and safer treatments for patients.
The technology is protected by 11 broad US patent and international patents. An additional patent has recently been allowed by the U.S. Patent Office.
Primary Application of the Technology
A market that is closely associated with sepsis is acute renal failure ("ARF"). ARF is a generic term defined as a decrease in renal function over a period of days. There are a number of causes of ARF, including septic shock, and despite hemodialysis and other advances in supportive care, mortality (when associated with multiple organ dysfunction), has remained high - ranging from 35% to greater than 90%. Use of this patented system to treat ARF is estimated to be a $500 million market.
Another market for this technology is avian flu. By modifying several product parameters it is expected that virus genetic material would be disrupted and the “cytokine storm” inherent with this flu would be attenuated.
The primary treatment for severe sepsis currently is antibiotic therapy. Typical treatment requires an extended hospital stay of 11 days, with much of this time being spent in the intensive care unit (ICU). Hospitals lose significant amounts of money on the treatment of septic patients and should thus be highly motivated to adopt a new therapy that both decreases the cost of treatment (by length of stay reduction) and reduces mortality. Some hospitals are unprofitable and may become profitable by adopting the patented system, especially when their annual severe sepsis caseload is above 200 patients. The seller believes that treatment of severe sepsis with the their system in conjunction with standard antibiotic therapy and other therapies will prove to be more effective than treatment with these therapies alone.
Comments on Deal Structure, Potential Terms and Restrictions
The seller may consider selling these patents individually.
Class 604: Surgery
Class A61L2: HUMAN NECESSITIES - MEDICAL OR VETERINARY SCIENCE; HYGIENE
METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, O. Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor .
Class A61M1: HUMAN NECESSITIES - MEDICAL OR VETERINARY SCIENCE; HYGIENE
DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY . Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems .